Literature DB >> 17353282

Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.

Theodor Chitlaru1, Orit Gat, Haim Grosfeld, Itzhak Inbar, Yael Gozlan, Avigdor Shafferman.   

Abstract

In a previous comparative proteomic study of Bacillus anthracis examining the influence of the virulence plasmids and of various growth conditions on the composition of the bacterial secretome, we identified 64 abundantly expressed proteins (T. Chitlaru, O. Gat, Y. Gozlan, N. Ariel, and A. Shafferman, J. Bacteriol. 188:3551-3571, 2006). Using a battery of sera from B. anthracis-infected animals, in the present study we demonstrated that 49 of these proteins are immunogenic. Thirty-eight B. anthracis immunogens are documented in this study for the first time. The relative immunogenicities of the 49 secreted proteins appear to span a >10,000-fold range. The proteins eliciting the highest humoral response in the course of infection include, in addition to the well-established immunogens protective antigen (PA), Sap, and EA1, GroEL (BA0267), AhpC (BA0345), MntA (BA3189), HtrA (BA3660), 2,3-cyclic nucleotide diesterase (BA4346), collagen adhesin (BAS5205), an alanine amidase (BA0898), and an endopeptidase (BA1952), as well as three proteins having unknown functions (BA0796, BA0799, and BA0307). Of these 14 highly potent secreted immunogens, 11 are known to be associated with virulence and pathogenicity in B. anthracis or in other bacterial pathogens. Combining the results reported here with the results of a similar study of the membranal proteome of B. anthracis (T. Chitlaru, N. Ariel, A. Zvi, M. Lion, B. Velan, A. Shafferman, and E. Elhanany, Proteomics 4:677-691, 2004) and the results obtained in a functional genomic search for immunogens (O. Gat, H. Grosfeld, N. Ariel, I. Inbar, G. Zaide, Y. Broder, A. Zvi, T. Chitlaru, Z. Altboum, D. Stein, S. Cohen, and A. Shafferman, Infect. Immun. 74:3987-4001, 2006), we generated a list of 84 in vivo-expressed immunogens for future evaluation for vaccine development, diagnostics, and/or therapeutic intervention. In a preliminary study, the efficacies of eight immunogens following DNA immunization of guinea pigs were compared to the efficacy of a PA DNA vaccine. All eight immunogens induced specific high antibody titers comparable to the titers elicited by PA; however, unlike PA, none of them provided protection against a lethal challenge (50 50% lethal doses) of virulent B. anthracis strain Vollum spores.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353282      PMCID: PMC1932864          DOI: 10.1128/IAI.02029-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  82 in total

1.  Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis.

Authors:  Oresta Vytvytska; Eszter Nagy; Martin Blüggel; Helmut E Meyer; Robert Kurzbauer; Lukas A Huber; Christoph S Klade
Journal:  Proteomics       Date:  2002-05       Impact factor: 3.984

2.  Macrophage-induced genes of Legionella pneumophila: protection from reactive intermediates and solute imbalance during intracellular growth.

Authors:  Susannah Rankin; Zhiru Li; Ralph R Isberg
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

Review 3.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  Pattern searches for the identification of putative lipoprotein genes in Gram-positive bacterial genomes.

Authors:  Iain C Sutcliffe; Dean J Harrington
Journal:  Microbiology       Date:  2002-07       Impact factor: 2.777

5.  A novel two-component regulatory system in Bacillus subtilis for the survival of severe secretion stress.

Authors:  H L Hyyryläinen; A Bolhuis; E Darmon; L Muukkonen; P Koski; M Vitikainen; M Sarvas; Z Prágai; S Bron; J M van Dijl; V P Kontinen
Journal:  Mol Microbiol       Date:  2001-09       Impact factor: 3.501

6.  Anthrax spores make an essential contribution to vaccine efficacy.

Authors:  Fabien Brossier; Martine Levy; Michèle Mock
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

7.  Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.

Authors:  David Kobiler; Yehoshua Gozes; Hagai Rosenberg; Dino Marcus; Shaul Reuveny; Zeev Altboum
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  Immunoproteomics of Helicobacter pylori infection and relation to gastric disease.

Authors:  Gaby Haas; Galip Karaali; Karl Ebermayer; Wolfram G Metzger; Stephanie Lamer; Ursula Zimny-Arndt; Susanne Diescher; Ulf B Goebel; Konstanze Vogt; Artur B Roznowski; Bertram J Wiedenmann; Thomas F Meyer; Toni Aebischer; Peter R Jungblut
Journal:  Proteomics       Date:  2002-03       Impact factor: 3.984

9.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

10.  Immunogenic proteins of Helicobacter pullorum, Helicobacter bilis and Helicobacter hepaticus identified by two-dimensional gel electrophoresis and immunoblotting.

Authors:  Iryna Kornilovs'ka; Ingrid Nilsson; Meeme Utt; Asa Ljungh; Torkel Wadström
Journal:  Proteomics       Date:  2002-06       Impact factor: 3.984

View more
  42 in total

1.  Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins.

Authors:  Koushik Roy; Scott Bartels; Firdausi Qadri; James M Fleckenstein
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

Review 2.  Vaccinology in the genome era.

Authors:  C Daniela Rinaudo; John L Telford; Rino Rappuoli; Kate L Seib
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

Review 3.  The adenylyl cyclase activity of anthrax edema factor.

Authors:  Wei-Jen Tang; Qing Guo
Journal:  Mol Aspects Med       Date:  2009-06-26

4.  The role of anthrolysin O in gut epithelial barrier disruption during Bacillus anthracis infection.

Authors:  Brian L Bishop; James P Lodolce; Lauren E Kolodziej; David L Boone; Wei Jen Tang
Journal:  Biochem Biophys Res Commun       Date:  2010-02-25       Impact factor: 3.575

Review 5.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

6.  Lipoprotein biosynthesis by prolipoprotein diacylglyceryl transferase is required for efficient spore germination and full virulence of Bacillus anthracis.

Authors:  Shu Okugawa; Mahtab Moayeri; Andrei P Pomerantsev; Inka Sastalla; Devorah Crown; Pradeep K Gupta; Stephen H Leppla
Journal:  Mol Microbiol       Date:  2011-11-22       Impact factor: 3.501

7.  The five near-iron transporter (NEAT) domain anthrax hemophore, IsdX2, scavenges heme from hemoglobin and transfers heme to the surface protein IsdC.

Authors:  Erin Sarah Honsa; Marian Fabian; Ana Maria Cardenas; John S Olson; Anthony William Maresso
Journal:  J Biol Chem       Date:  2011-08-01       Impact factor: 5.157

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

9.  Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV).

Authors:  Yong-Zhang Zhu; Cheng-Song Cai; Wei Zhang; Hong-Xiong Guo; Jin-Ping Zhang; Ya-Yong Ji; Guang-Yuan Ma; Jia-Lin Wu; Qing-Tian Li; Cheng-Ping Lu; Xiao-Kui Guo
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

10.  Secretome: clues into pathogen infection and clinical applications.

Authors:  Shoba Ranganathan; Gagan Garg
Journal:  Genome Med       Date:  2009-11-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.